Summary: In a 72-week clinical trial, participants lost an average of 20.2 % of their body weight compared to 13.7 % of semaglutide ( Wegovy ). The study instantly compared the two medications when they were taken at their highest concentrations in persons who were obese but not diabetic.
Researchers attribute the superiority of tirzepatide’s two actions on both GLP-1 and GIP testosterone receptors, which promotes metabolic and appetite-suppression effects. While both medications had related side effects, such as nausea and chest discomfort, tirzepatide more than doubled the percentage of patients who lost more than 25 % of their weight lost.
Important Information
- Greater Effectiveness: Tirzepatide reduced average weight by 50 lbs compared to semaglutide, which produced a 33 pound loss.
- Two Mechanism: Tirzepatide increases its outcomes by enhancing both GLP-1 and GIP receptor.
- Broader Impact: Compared to semaglutide, 32 % of people who take tirazole lost at least 25 % of their body weight.
Weill Cornell University as the cause
In a clinical trial that compared the safety and efficacy of the injectable medications, Tirzepatide ( trade name Zepbound ) and semaglutide ( trade name Wegovy ) both showed greater weight loss in obese people.
Participants in the 72-week trial, which was led by investigators from Weill Cornell Medicine and New York-Presbyterian and was conducted with the University of Texas McGovern Medical School, the David Geffen School of Medicine at the University of California, Los Angeles, the University College Dublin, and Eli Lilly, lost about 50 pounds, or 20.2 % of their body weight, compared to those on semaglutide, who lost an average of 33 weight, or 13.7 % of their benchmark fat.
The SURMOUNT-5 step 3b , study, which was published on May 11 in the New England Journal of Medicine, found that participants who took tirzepatide were more likely to lose weight and saw a greater decline in waist circumference than those who took semaglutide.
The result may not have come as a surprise in some ways.
The benefits are in line with what we’ve seen in independent trial studies of these drugs, according to Dr. Louis Aronne, the chairman of the Comprehensive Weight Control Center and the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medicine and lead analyst of SURMOUNT-5.
For instance, Dr. Aronne led a study in 2022 that found a body-weight loss of 14.9 % after a 72-week course of tiridine at its highest dosage. A similar study published in 2021  reported a 14.9 % loss with semaglutide after 68 weeks.
A Head-to-Head Evaluation
The advantage of this study, a randomized, controlled trial of 751 people who have type 2 diabetes but are obese, is that the medication can be compared head-to-head.
” Physicians, insurance companies, and individuals are generally enquiring about which medication is more effective.” Dr. Aronne, a diabetes and obesity endocrinologist at NewYork-Presbyterian/Weill Cornell Medical Center, said.
” This study gave us the opportunity to conduct a strong evaluation.”
However, the test was not conducted as a overwhelmed analysis, which is the gold standard for reducing discrimination in scientific studies. Participants were aware of the drugs they were receiving because these medications are administered via labeled auto-injection products.
The research was sponsored by Eli Lilly, a company that makes tirzepatide. It was examined at 32 locations throughout the US and Puerto Rico. All participants were given diet and exercise guidance, and the side effects of both medications were very similar.
For instance, about 44 % of those in each treatment arm reported nausea and 25 % of people reported abdominal pain.
Nearly one-third ( 32 % ) of those taking tirzepatide managed to reduce their body-weight by at least 25 %, compared to 16 % of those taking semaglutide.
According to Dr. Aronne, the improved efficiency is likely related to tirzepatide’s two mechanism of action.
Tidepatide mimics both GLP-1 and an additional hormone, glucose-dependent insulinotropic peptide ( GIP), while semaglutide works by activating receptors for a hormone called glucagon-like peptide 1, or GLP-1. These behaviors all contribute to reducing poverty, lowering blood glucose levels, and altering large cell metabolism.
According to Dr. Aronne,” the mechanisms that control weight are very complex.” The ability to combine several methods may be paved the way for weight loss additively.
Studies are being conducted to see if tirzepatide, along with semaglutide, lowers the risk of cardiovascular events like heart attacks and strokes.
Generation X
Dr. Aronne and his colleagues are now testing the newest generation of weight-loss medications, including those known as Eli Lilly’s retatrutide, nicknamed” triple G” for the three hormone it mimics: GLP-1, GIP, and glucagon. Medicines like retatrutide have the potential to gain a wider population in addition to being probably more efficient.
” We also have citizens who don’t respond to medication like tirzepatide and semaglutide, even though they work really well, better than anything we have always seen,” said Dr. Aronne.
We want to stay trying to do much, but moving forward.
Note: Dr. Louis Aronne works for Eli Lilly and Company, the study sponsor, and Zepbound (tirzepatide ) manufacturer for a fee as a consultant and member of the advisory board.
Dr. Aronne even serves on Novo Nordisk’s paid advisory panel, which manufactures semaglutide.
About this information about neuropharmacology and fat reduction
Author: Krystle Lopez
Source: Weill Cornell University
Contact: Krystle Lopez – Weill Cornell University
Image: The image is credited to Neuroscience News
Initial research has been made private.
The study” Tirzepatide as Compared to Semaglutide for the Treatment of Obesity” by Louis Aronne and as. NEJM
Abstract
Tirzepatide and Semaglutide for the Obesity Treatment
Background
Semaglutide and tirzapatide are potent weight-loss treatments. In people with fat but not type 2 diabetes, the safety and efficacy of tirzepatide as compared to semaglutide is unknown.
Methods
Adult participants with obesity who were randomly assigned in a 1: 1 ratio in this phase 3b, open-label, controlled trial were given the maximum tolerated dose of semaglutide or tirzepatide ( 10 mg or 15 mg ) or the maximum tolerated dose of semaglutide ( 1. 7 mg or 2.4 mg ) subcutaneously once weekly for 72 weeks.
The fat change rate from foundation to month 72 was the main goal. At least 10 %, 15 %, 20 %, and 25 % weight reductions and a change in waist circumference from baseline to week 72 were the other key secondary endpoints.
Results
Randomization was performed on 751 individuals overall. The least-squares mean percent change in weight at week 72 was −20.2 % (95 % confidence interval]CI], −21.4 to −19.1 ) with tirzepatide and −13.7 % (95 % CI, −14.9 to −12.6 ) with semaglutide ( P<, 0.001 ). The least-squares mean change in waist circumference was −18.4 cm (95 % CI, −19.6 to −17.2 ) with tirzepatide and −13.0 cm (95 % CI, −14.3 to −11.7 ) with semaglutide ( P<, 0.001 ).
Participants in the tirzepatide group had weight reductions of at least 10 %, 15 %, 20 %, and 25 % more frequently than those in the semaglutide group. The most frequent adverse events in both cure groups were digestive, and the majority of them were mild to moderate in intensity and usually occurred during dosage escalation.
Conclusions
At month 72, participants who had fat but who didn’t have diabetes were treated with tirzepatide more effectively than semaglutide, both in terms of body fat and waist circumference reduction.
Funding
( Funded by Eli Lilly, SURMOUNT-5 ClinicalTrials. gov number,  , NCT05822830. )
